# Targeting Cancer Cells with Smart, Internalizing Antibodies

> This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.

- **Patent:** US 20230076417
- **Original title:** Multispecific antigen-binding molecule with improved internalization characteristics
- **Owner:** Genmab AS
- **Status:** Active
- **Times cited:** 1
- **Field:** biotech, pharmaceutical, oncology

## What it does

This patent describes a special molecule, like an antibody, that has two specific parts, called antigen-binding domains. The first part is designed to attach to a 'target molecule (T)' often found on cancer cells (Claim 1). The second part attaches to an 'internalizing effector protein (E)' (Claim 1), which is a protein on the cell surface that helps pull things inside. The key feature is that this second part has a very specific binding strength, or 'dissociation constant (KD),' for the effector protein (E), set between 10^-9 and 10^-8 M (Claim 1). This precise binding strength helps the entire molecule get pulled into the cell more efficiently, especially when the target molecule (T) is also present (Claim 8, 10). For example, a HER2xCD63 bispecific antibody (Claim 36) could be designed to deliver a drug inside HER2-positive cancer cells.

## What it does NOT cover

- Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).
- Multispecific antibodies where the second binding domain's affinity (KD) for the internalizing effector protein (E) is outside the specified 10^-9 to 10^-8 M range (Claim 1).
- Molecules that internalize into cells without requiring the presence of the target molecule (T) for enhanced internalization (Claim 8).
- Molecules where the effector protein (E) is not a cell surface molecule that is internalized into the cell (Claim 7).
- Molecules where the target (T) is not associated with a tumor or cancer (Abstract, Claim 35).

## The clever bit

The clever part is precisely defining the optimal binding strength (dissociation constant) for the second antigen-binding domain to an internalizing effector protein. This specific affinity range (10^-9 to 10^-8 M) is crucial for ensuring the molecule not only binds to the cell but also gets efficiently pulled inside and transported to the lysosomal compartment, especially when the cancer target is present (Claim 1, 10). This fine-tuning enhances targeted delivery.

## Real-world examples

1. Antibody-drug conjugates (ADCs) for cancer treatment
2. Bispecific antibodies designed to deliver drugs into tumor cells
3. HER2-targeting therapies that require cellular uptake
4. CD63-targeting therapies for enhanced internalization

## Why it matters

This technology aims to improve how therapeutic molecules, like drugs, are delivered into cancer cells. Many effective cancer treatments need to get inside the cell to work properly. By making the delivery process more efficient and specific to cancer cells, this approach could lead to more potent treatments with fewer side effects, potentially improving patient outcomes.

## Frequently asked questions

### What does Targeting Cancer Cells with Smart, Internalizing Antibodies cover?

This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.

### Who owns patent US 20230076417?

This patent is owned by Genmab AS.

### When does this patent expire?

This patent is expected to expire on April 6, 2042, when the invention enters the public domain.

### What is patent US 20230076417 cited by?

This patent has been cited by 1 later patents that build on its ideas.

### What problem does this patent solve?

This technology aims to improve how therapeutic molecules, like drugs, are delivered into cancer cells. Many effective cancer treatments need to get inside the cell to work properly. By making the delivery process more efficient and specific to cancer cells, this approach could lead to more potent treatments with fewer side effects, potentially improving patient outcomes.

### What does this patent NOT cover?

Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).

**Full plain-English explainer:** https://patentbrief.org/patent/us/20230076417/multispecific-antigen-binding-molecule-with-improved-internalization-characteris

**Original patent:** https://patents.google.com/patent/US20230076417

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [How to Measure Unbound Drug Target in a Sample](https://patentbrief.org/patent/us/20210055304/method-for-the-detection-of-a-binding-partner-of-a-multispecific-binder) — This patent describes a laboratory method for accurately measuring the amount of a specific target molecule (antigen) that is not yet bound by a complex drug (multispecific antibody) in a sample, which is important for drug development.
- [How Roche Engineers Antibodies to Target Two Different Diseases Simultaneously](https://patentbrief.org/patent/us/10138293/opdivo-nivolumab) — A method for creating a custom-engineered antibody that can grab onto two different targets at once, designed to help the immune system fight complex diseases.
- [Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds](https://patentbrief.org/patent/us/20210301031/napi2b-targeted-antibody-drug-conjugates-and-methods-of-use-thereof) — This patent describes a new way to deliver powerful cancer drugs directly to tumor cells using a specific antibody attached to a special polymer, aiming to reduce side effects.
- [Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease](https://patentbrief.org/patent/us/20210205465/aberrant-cell-restricted-immunoglobulins-provided-with-a-toxic-moiety) — This patent describes special antibodies equipped with a toxic payload that specifically seek out and bind to unique markers on diseased cells, like cancer or autoimmune cells, to destroy them.
- [A Chemical Linker for Attaching Drugs to Antibodies](https://patentbrief.org/patent/us/10772965/covalent-linkers-in-antibody-drug-conjugates-and-methods-of-making-and-using-the) — This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.
